Last reviewed · How we verify
NCT04792281: PET-NAVIE
Impact of FDG-PET/CT on Management of Patients with Native Valve Infective Endocarditis
trial in Infective Endocarditis in 97 participants. Currently enrolling.
31 December 2025
Quick facts
| Lead sponsor | Montreal Heart Institute |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 97 |
| Start date | 31 August 2021 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 6 locations across Canada |
Conditions studied
- Infective Endocarditis — all drugs for Infective Endocarditis →
- Native Valve Endocarditis — all drugs for Native Valve Endocarditis →
Sponsor
Montreal Heart Institute
Who can join
18 and older, any sex, with Infective Endocarditis or Native Valve Endocarditis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The proposed study is a multicentric prospective observational cohort study of patients with suspected NVE. The study population includes those with Possible IE according to the modified Duke criteria and investigated at one of the 6 participating sites which include 2 cardiac centers, the MHI and the IUCPQ, as well as 4 tertiary care centers, the Jewish General Hospital , the McGill University Health Centre and the CHUS.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04792281
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Infective Endocarditis
Currently open trials in the same condition.
- NCT06269679 — CBCT vs OPT on the Oral Health Status at 12 Months of Patients Hospitalized for Infective Endocarditis. · NA · recruiting
- NCT05965362 — Prognosis of Patients With Infective Endocarditis and Risk Stratification Value of Biomarkers (ENDEAVOR） · recruiting
- NCT06418048 — INfectious DIsease REgistry BIObank · recruiting
- NCT07156292 — The Epidemiology Change From 2006 to 2022 of Infective Endocarditis in Taiwan · active not recruiting
- NCT06309680 — Accuracy of Metagenomic Blood Sampling to Identify Pathogen in Infective Endocarditis Patients · active not recruiting
Other Montreal Heart Institute trials
Trials by the same sponsor.
- NCT07524335 — Aspirin in Subclinical Coronary Artery Disease: A Pilot Randomised Controlled Trial · Phase 3 · not yet recruiting
- NCT07257198 — Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone · Phase 3 · recruiting
- NCT07391358 — DAPT Strategy in HBR Patients Undergoing Complex PCI Following ACS: Second-Phase Beta Testing of a Patients Decision Aid · NA · not yet recruiting
- NCT05450328 — Inhaled Milrinone and Epoprostenol for the Prevention of Difficult Cardiac Pulmonary Bypass Separation · Phase 2 · not yet recruiting
- NCT07144722 — Prehabilitation Program for Patients Awaiting Elective Heart Surgery at Increased Risk of Postoperative Complications: F · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04792281 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Montreal Heart Institute
- Last refreshed: 22 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04792281.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing